
|Articles|February 15, 2003
Foresighted
Novartis Ophthalmics and Valley Forge Pharmaceuticals Inc. have entered into a licensing agreement for a novel eye medication for myopia, which in phase II clinical trials reduced progression of the disease by 50% in the first 12 months of therapy.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement


















































.png)


